CVRdatabase
Menu

Avilex Pharma ApS

Private limited companyCVR 34896828København ØActive

Avilex Pharma ApS is a private limited company, based in København Ø, active in research and experimental development on natural sciences and engineering, founded in 2012. Equity was negative at the end of 2025 (−DKK 10.8m). The company made a loss in both 2024 and 2025, most recently DKK 4.5m.

Follow
PDF reportCompare

Key figures · financial year 2025

Net profit−DKK 4.5m−2.3% vs. 2024
Equity−DKK 10.8m−72.3% vs. 2024
Employees4latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 4.4m to DKK 4.5m (2024 → 2025).

Management and owners, last 24 months

  • New in management: Camilla Petrycer Hansen (board member, 06/06/2025).
  • Stepped down: Morten Døssing (board member, 06/06/2025).

Registrations, last 24 months

  • 03/08/2026: Moved to Jagtvej 162, 2100 København Ø
  • 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 30m−DKK 20m−DKK 10mDKK 0DKK 10mDKK 20mDKK 30m202020212022202320242025
EquityNet profit
Financial figures for Avilex Pharma ApS
202020212022202320242025Change
Revenuenot statednot stated45,4790not statednot stated–
Gross profit−3,133–45,4790–––
Operating profit (EBIT)–−8,68434,858−6,034−4,803−4,240+11.7%
Profit before tax−3,978−9,62636,661−8,700−4,735−5,820−22.9%
Net profit−3,042−6,61128,600−6,756−4,428−4,530−2.3%
Total assets9,3754,91731,59127,87521,55918,391−14.7%
Equity−18,649−25,2604,917−1,839−6,267−10,797−72.3%
Liabilities28,02430,17726,67429,71427,82629,188+4.9%
Cash and cash equivalents7,50959829,82724,57920,06716,928−15.6%
Average number of employees2222220%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 10mDKK 0DKK 10mDKK 20mDKK 30mDKK 40mDKK 50m202020212022202320242025
Gross profitMedian, the industry (431 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 10.8m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 3 years in a row

    Net result has been negative in 2023–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Avilex Pharma ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202521/07/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202425/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202303/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202205/07/2023The companyPDFXBRL
202101/01/2021 – 31/12/202102/05/2022The companyPDFXBRL
202001/01/2020 – 31/12/202019/04/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0123401/2302/2303/2304/2305/2306/2307/2308/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/25
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

Equity−DKK 10.8mNo. 404 of 431
Better than 6% of the companies in the industry
Number of employees4No. 290 of 431
Better than 33% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale).

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparisonnot stated
No. 69,614of 69,964
Better than 1%
Same industry and fewer than 20 employees329 companies in the comparisonnot stated
No. 313of 329
Better than 5%
Companies that are between 5 and 14 years old33,688 companies in the comparisonnot stated
No. 33,377of 33,687
Better than 1%
All companies of type ApS66,508 companies in the comparisonnot stated
No. 66,157of 66,505
Better than 1%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. Avilex Pharma ApSDKK 0
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. Avilex Pharma ApS−DKK 4.5m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. Avilex Pharma ApS−DKK 10.8m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. Avilex Pharma ApS4
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
Avilex Pharma ApS

Management

5 active registrations

Executive management

Executive management at Avilex Pharma ApS
NameRoleAppointed
Kristian StrømgaardDirector17/01/2016

Board of directors

Board of directors at Avilex Pharma ApS
NameRoleAppointed
Kristian StrømgaardBoard member27/12/2012
Raymond George HillChair of the board20/05/2016
Jonathan Mark TreherneBoard member01/05/2018
Camilla Petrycer HansenBoard member06/06/2025
Founders
Anders Bach
Former management (12)
Former management at Avilex Pharma ApS
NameRoleAppointedResigned
Anders BachBoard member27/12/201218/02/2013
Ingelise SaundersChair of the board18/02/201302/01/2014
Robert Giles TansleyCEO18/02/201301/07/2013
Raymond George HillBoard member18/02/201319/05/2016
Nanna Liebach LüneborgDirector01/07/201331/12/2013
Kristian StrømgaardCEO31/12/201316/01/2016
Henrijette Elsebeth RichterChair of the board02/01/201402/09/2014
Bobby G SoniChair of the board02/09/201414/08/2015
Emmanuelle CoutanceauChair of the board01/09/201519/05/2016
Jonathan Mark TreherneCEO17/01/201601/05/2018
Emmanuelle CoutanceauBoard member20/05/201621/12/2018
Morten DøssingBoard member21/12/201806/06/2025

Signing rule: Selskabet tegnes af en direktør i forening med bestyrelsesformanden, eller af to bestyrelsesmedlemmer i forening, eller af bestyrelsesformanden i forening med et andet bestyrelsesmedlem.

Address and production units

1 active production units

Jagtvej 162
2100 København Ø

København Municipality · Postcode 2100

Production units
Production unitAddressEmployeesP number
AVILEX PHARMA ApSJagtvej 162, 2100 København Ø41018162918

Purpose

Selskabets formål er udvikling af behandlingsmæssige peptider eller afledte peptider (monomer, dimer og trimer) eller små molekylære forbindelser som er rettet mod PDZ domæner og relateret virksomhed besluttet af bestyrelsen.

The purpose is quoted from the register in Danish.

Changes year by year

64 registered events
20262 changesaddress 1 · accounts 1
  • Moved to Jagtvej 162, 2100 København Ø
  • Annual report for 2025 published
20254 changesaccounts 1 · management 2 · industry 1
  • Annual report for 2024 published
  • Camilla Petrycer Hansen appointed board member
  • Morten Døssing stepped down as board member
  • Industry changed to Research and experimental development on natural sciences and engineering (721000)
20241 changeaccounts 1
  • Annual report for 2023 published
20231 changeaccounts 1
  • Annual report for 2022 published
20224 changescapital 1 · ownership 2 · accounts 1
  • Share capital changed from 408,686 DKK to 469,198 DKK
  • Novo Holdings A/S registered as owner (50%)
  • Novo Holdings A/S is no longer registered as owner
  • Annual report for 2021 published
20211 changeaccounts 1
  • Annual report for 2020 published
20197 changesownership 7
  • KRISTIAN STRØMGAARD HOLDING ApS registered as owner (20%)
  • Anders Bach ApS registered as owner (10%)
  • MIKAEL SØNDERGÅRD THOMSEN ApS registered as owner (5%)
  • Kristian Strømgaard is no longer registered as owner
  • Mikael Søndergaard Thomsen is no longer registered as owner
  • Anders Bach ApS is no longer registered as owner
  • KRISTIAN STRØMGAARD HOLDING ApS is no longer registered as owner
201813 changescapital 1 · management 4 · ownership 8
  • Share capital changed from 283,686 DKK to 408,686 DKK
  • Morten Døssing appointed board member
  • Emmanuelle Coutanceau stepped down as board member
  • Anders Bach ApS registered as owner (5%)
  • Kristian Strømgaard registered as owner (10%)
  • Novo Holdings A/S registered as owner (33.33%)
  • KRISTIAN STRØMGAARD HOLDING ApS registered as owner (5%)
  • Mikael Søndergaard Thomsen registered as owner (5%)
  • Novo Holdings A/S is no longer registered as owner
  • Anders Bach ApS is no longer registered as owner
  • KRISTIAN STRØMGAARD HOLDING ApS is no longer registered as owner
  • Jonathan Mark Treherne appointed board member
  • Jonathan Mark Treherne stepped down as ceo
20167 changesmanagement 7
  • Raymond George Hill appointed chair of the board
  • Emmanuelle Coutanceau appointed board member
  • Emmanuelle Coutanceau stepped down as chair of the board
  • Raymond George Hill stepped down as board member
  • Jonathan Mark Treherne appointed ceo
  • Kristian Strømgaard appointed director
  • Kristian Strømgaard stepped down as ceo
20156 changesmanagement 2 · capital 1 · ownership 2 · address 1
  • Emmanuelle Coutanceau appointed chair of the board
  • Bobby G Soni stepped down as chair of the board
  • Share capital changed from 80,000 DKK to 283,686 DKK
  • Novo Holdings A/S registered as owner (66.67%)
  • Moved to Ole Maaløes Vej 3, 2200 København N
  • Anders Bach ApS registered as owner (10%)
20145 changesaddress 1 · management 4
  • Moved to Jagtvej 162, 2100 København Ø
  • Bobby G Soni appointed chair of the board
  • Henrijette Elsebeth Richter stepped down as chair of the board
  • Henrijette Elsebeth Richter appointed chair of the board
  • Ingelise Saunders stepped down as chair of the board
20139 changesmanagement 8 · industry 1
  • Kristian Strømgaard appointed ceo
  • Nanna Liebach Lüneborg stepped down as director
  • Nanna Liebach Lüneborg appointed director
  • Robert Giles Tansley stepped down as ceo
  • Robert Giles Tansley appointed ceo
  • Ingelise Saunders appointed chair of the board
  • Raymond George Hill appointed board member
  • Anders Bach stepped down as board member
  • Industry changed to Forskning og eksperimentel udvikling indenfor bioteknologi (721100)
20124 changesfounded 1 · management 2 · ownership 1
  • Registered as AVILEX PHARMA ApS
  • Kristian Strømgaard appointed board member
  • Anders Bach appointed board member
  • KRISTIAN STRØMGAARD HOLDING ApS registered as owner (10%)

Related companies

Same industry in København

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction